Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Gene | MAP2K1 |
Variant | I99_K104del |
Impact List | deletion |
Protein Effect | gain of function |
Gene Variant Descriptions | MAP2K1 I99_K104del results in the deletion of six amino acids in the Map2k1 protein from amino acids 99 to 104 (UniProt.org). I99_K104del confers a gain of function to the Map2k1 protein as demonstrated by Raf-independent activity, increased phosphorylation of Mek and Erk (PMID: 29483135), increased proliferation in a competition assay, and increased transformation in cultured cells (PMID: 36442478). |
Associated Drug Resistance | |
Category Variants Paths |
MAP2K1 mutant MAP2K1 act mut MAP2K1 I99_K104del |
Transcript | NM_002755.4 |
gDNA | chr15:g.66436749_66436766del18 |
cDNA | c.295_312del18 |
Protein | p.I99_K104delIHLEIK |
Source Database | RefSeq |
Genome Build | GRCh38/hg38 |
Transcript | gDNA | cDNA | Protein | Source Database | Genome Build |
---|---|---|---|---|---|
XM_011521783.4 | chr15:g.66436815_66436832del18 | c.295_312del18 | p.C99_I104delCNSPYI | RefSeq | GRCh38/hg38 |
NM_002755.3 | chr15:g.66436749_66436766del18 | c.295_312del18 | p.I99_K104delIHLEIK | RefSeq | GRCh38/hg38 |
XM_017022411 | chr15:g.66436749_66436766del18 | c.295_312del18 | p.I99_K104delIHLEIK | RefSeq | GRCh38/hg38 |
NM_002755 | chr15:g.66436749_66436766del18 | c.295_312del18 | p.I99_K104delIHLEIK | RefSeq | GRCh38/hg38 |
XM_017022413.1 | chr15:g.66485119_66485136del18 | c.295_312del18 | p.F99_E104delFGCQVE | RefSeq | GRCh38/hg38 |
XM_017022412.1 | chr15:g.66436815_66436832del18 | c.295_312del18 | p.C99_I104delCNSPYI | RefSeq | GRCh38/hg38 |
NM_002755.4 | chr15:g.66436749_66436766del18 | c.295_312del18 | p.I99_K104delIHLEIK | RefSeq | GRCh38/hg38 |
XM_011521783.3 | chr15:g.66436815_66436832del18 | c.295_312del18 | p.C99_I104delCNSPYI | RefSeq | GRCh38/hg38 |
NM_001411065.1 | chr15:g.66436815_66436832del18 | c.295_312del18 | p.C99_I104delCNSPYI | RefSeq | GRCh38/hg38 |
XM_011521783 | chr15:g.66436815_66436832del18 | c.295_312del18 | p.C99_I104delCNSPYI | RefSeq | GRCh38/hg38 |
XM_017022411.3 | chr15:g.66436749_66436766del18 | c.295_312del18 | p.I99_K104delIHLEIK | RefSeq | GRCh38/hg38 |
XM_017022413 | chr15:g.66485119_66485136del18 | c.295_312del18 | p.F99_E104delFGCQVE | RefSeq | GRCh38/hg38 |
XM_017022412 | chr15:g.66436815_66436832del18 | c.295_312del18 | p.C99_I104delCNSPYI | RefSeq | GRCh38/hg38 |
XM_017022411.2 | chr15:g.66436749_66436766del18 | c.295_312del18 | p.I99_K104delIHLEIK | RefSeq | GRCh38/hg38 |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
MAP2K1 I99_K104del | Advanced Solid Tumor | resistant | Trametinib | Preclinical - Cell culture | Actionable | In a preclinical study, transformed cells expressing MAP2K1 I99_K104del were resistant to Mekinist (trametinib) in culture (PMID: 36442478). | 36442478 |